Esprit™ BTK

Everolimus Eluting Resorbable Scaffold

Esprit BTK

Esprit™ BTK System5

The PLLA resorbable scaffold supports the treated artery to address vessel recoil and dissection1, while the sustained everolimus elution inhibits restenosis and maximizes patency5. Ultimately the scaffold is completely resorbed*, leaving nothing behind.

Esprit BTK Resorption Diagram

Esprit™ BTK System resorption timeline

After the scaffold has been implanted and delivers the drug into the vessel, it begins to resorb naturally and disappear into the body over time like dissolving stitches, with complete resorption.5

Esprit BTK Resorption Timeline

Representative photomicrographs of porcine coronary arteries implanted with Absorb BVS (1–48 months). Data on file at Abbott.

*Excluding platinum markers.

References

  1. Esprit™ BTK Everolimus Eluting Resorbable Scaffold System Instructions for Use (IFU).
  2. Parikh, S. LIFE-BTK: The Top Line Results and Beyond. Presented at TCT 2023.
  3. Varcoe, RL., et al. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Engl J Med 2023; 390:9-19. Supplementary Appendix.
  4. Data on file at Abbott. Testing done with XIENCE Sierra™ 3.5 x 38 mm at nominal.
  5. Data on file at Abbott.

MAT-2408195 v1.0